Effect of liverpower on liver function in fatty liver

Assessing the effect of liverpower supplement on liver function in patients with fatty liver comparing to placebo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140804018677N11

Enrollment

Registered

2021-08-09

Start date

2021-07-10

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Intervention group: liverpower (500 mg), Ghaem darou company, three times daily for12 weeks. Intervention 2: Control group: Placebo contain maltodextrine, (500 mg)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Liver function enzymes higher than normal level Fatty liver diagnosis based on sonography Age>18 years Willing to participate in the study

Exclusion criteria

Exclusion criteria: Having known kidney disease Having known heart disease Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase (ALT) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kits.;Aspartate transaminase (AST) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kits.;Alkaline phosphatase (Alk-ph) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Razeghi Jahromi

Shahid Beheshti University of Medical Sciences

soodehrazeghi@gmail.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026